CU23779B7 - Compuestos de pirazolina y su uso y composiciones farmacéuticas - Google Patents

Compuestos de pirazolina y su uso y composiciones farmacéuticas

Info

Publication number
CU23779B7
CU23779B7 CU20090058A CU20090058A CU23779B7 CU 23779 B7 CU23779 B7 CU 23779B7 CU 20090058 A CU20090058 A CU 20090058A CU 20090058 A CU20090058 A CU 20090058A CU 23779 B7 CU23779 B7 CU 23779B7
Authority
CU
Cuba
Prior art keywords
compounds
pharmaceutical compositions
pirazoline
pirazoline compounds
formula
Prior art date
Application number
CU20090058A
Other languages
English (en)
Other versions
CU20090058A7 (es
Inventor
Joseph Gerace Rico
David Bruce Reitz
Marvin Jay Meyers
Matthew William Mahoney
Scott Allen Long
Susan Landis Hockerman
Xiangyang Chen
Graciela Barbieri Arhancet
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CU20090058A7 publication Critical patent/CU20090058A7/es
Publication of CU23779B7 publication Critical patent/CU23779B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de los compuestos, donde los compuestos tienen la estructura de fórmula I: ESPACIO PARA FÓRMULA (I) en la que R1, R2, R3A, R3B, R4, R5, R6, R7, R8 y X son comno se han definido en la descripción detallada de la invención. También se describen composiciones farmacéuticas, procedimientos de tratamiento e intermedios correspondientes.
CU20090058A 2006-10-31 2009-04-17 Compuestos de pirazolina y su uso y composiciones farmacéuticas CU23779B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86360606P 2006-10-31 2006-10-31

Publications (2)

Publication Number Publication Date
CU20090058A7 CU20090058A7 (es) 2011-07-11
CU23779B7 true CU23779B7 (es) 2012-02-15

Family

ID=39027523

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090058A CU23779B7 (es) 2006-10-31 2009-04-17 Compuestos de pirazolina y su uso y composiciones farmacéuticas

Country Status (40)

Country Link
US (3) US7781428B2 (es)
EP (1) EP2089367B1 (es)
JP (1) JP4977760B2 (es)
KR (1) KR101107800B1 (es)
CN (1) CN101541757A (es)
AP (1) AP2527A (es)
AR (1) AR063529A1 (es)
AT (1) ATE537151T1 (es)
AU (1) AU2007315884B2 (es)
BR (1) BRPI0717937A2 (es)
CA (1) CA2667966C (es)
CL (1) CL2007003154A1 (es)
CO (1) CO6160307A2 (es)
CR (1) CR10725A (es)
CU (1) CU23779B7 (es)
CY (1) CY1112311T1 (es)
DK (1) DK2089367T3 (es)
EA (1) EA016370B1 (es)
ES (1) ES2375877T3 (es)
GE (1) GEP20115239B (es)
GT (1) GT200700096A (es)
HN (1) HN2007000437A (es)
HR (1) HRP20120078T1 (es)
IL (1) IL198241A0 (es)
MA (1) MA30821B1 (es)
MX (1) MX2009004662A (es)
MY (1) MY145795A (es)
NI (1) NI200900071A (es)
NO (1) NO20091741L (es)
NZ (1) NZ575923A (es)
PE (1) PE20081472A1 (es)
PL (1) PL2089367T3 (es)
PT (1) PT2089367E (es)
RS (2) RS52203B (es)
SI (1) SI2089367T1 (es)
TN (1) TN2009000160A1 (es)
TW (1) TWI357327B (es)
UA (1) UA92670C2 (es)
UY (1) UY30670A1 (es)
WO (1) WO2008053300A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
WO2011059784A1 (en) * 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
ES2641144T3 (es) 2010-05-10 2017-11-07 Inserm (Institut National De La Santé Et De La Recherche Medicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
WO2012048022A2 (en) * 2010-10-05 2012-04-12 Nova Southeastern University Methods and compositions for therapeutic modulation of aldosterone levels in heart disease
RS58274B1 (sr) 2014-06-30 2019-03-29 Astrazeneca Ab Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN113679716B (zh) 2021-10-13 2024-03-26 史大永 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) * 2022-01-04 2023-06-09 中山大学 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086068A (en) * 1964-09-02 1967-10-04 Ici Ltd Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) * 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) * 1988-09-30 1989-09-12 Eastman Kodak Company Thermally-transferable fluorescent diphenylpyrazolines
ES2098547T3 (es) * 1992-01-23 1997-05-01 Pfizer Benzopirano y otros antagonistas de ltb4 relacionados.
GB9318691D0 (en) 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
WO1998009969A1 (en) * 1996-09-05 1998-03-12 Astra Pharmaceuticals Ltd. Novel aryl-pyridazines
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
WO1999055335A1 (en) 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
US6432974B1 (en) * 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003078394A1 (en) 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
DE60308387T2 (de) 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
PL375979A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
BRPI0406883A (pt) 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MXPA06007055A (es) * 2003-12-19 2007-01-30 Lilly Co Eli Moduladores del receptor nuclear de hormona esteroide triciclica.
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
EP1773768B8 (en) 2004-07-30 2018-12-26 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
EP1844020B1 (en) 2005-01-10 2017-09-06 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
JPWO2006077821A1 (ja) 2005-01-19 2008-06-19 大日本住友製薬株式会社 アルドステロン受容体調節剤としての芳香族スルホン化合物
US7595337B2 (en) 2005-02-10 2009-09-29 Merck & Co. Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
UA92670C2 (ru) 2010-11-25
WO2008053300A1 (en) 2008-05-08
HRP20120078T1 (hr) 2012-02-29
AU2007315884B2 (en) 2012-10-04
JP4977760B2 (ja) 2012-07-18
AR063529A1 (es) 2009-01-28
CR10725A (es) 2009-05-12
KR101107800B1 (ko) 2012-01-25
MX2009004662A (es) 2009-05-22
CA2667966C (en) 2011-08-02
PT2089367E (pt) 2012-02-01
US20080167294A1 (en) 2008-07-10
CA2667966A1 (en) 2008-05-08
CO6160307A2 (es) 2010-05-20
CY1112311T1 (el) 2015-12-09
SI2089367T1 (sl) 2012-02-29
US20120035131A1 (en) 2012-02-09
CN101541757A (zh) 2009-09-23
NZ575923A (en) 2011-01-28
US20100280016A1 (en) 2010-11-04
CU20090058A7 (es) 2011-07-11
UY30670A1 (es) 2008-05-31
GEP20115239B (en) 2011-06-10
HN2007000437A (es) 2011-01-17
PE20081472A1 (es) 2008-10-18
BRPI0717937A2 (pt) 2013-12-03
RS52203B (sr) 2012-10-31
US7781428B2 (en) 2010-08-24
IL198241A0 (en) 2009-12-24
EP2089367A1 (en) 2009-08-19
NI200900071A (es) 2010-03-08
EA016370B1 (ru) 2012-04-30
DK2089367T3 (da) 2012-02-06
EA200970341A1 (ru) 2009-10-30
PL2089367T3 (pl) 2012-04-30
JP2010508257A (ja) 2010-03-18
CL2007003154A1 (es) 2008-05-09
NO20091741L (no) 2009-05-29
RS20090208A (sr) 2010-06-30
MY145795A (en) 2012-04-30
TN2009000160A1 (fr) 2010-10-18
EP2089367B1 (en) 2011-12-14
AP2009004822A0 (en) 2009-04-30
GT200700096A (es) 2010-07-15
TWI357327B (en) 2012-02-01
ES2375877T3 (es) 2012-03-07
ATE537151T1 (de) 2011-12-15
KR20090060371A (ko) 2009-06-11
MA30821B1 (fr) 2009-10-01
AU2007315884A1 (en) 2008-05-08
AP2527A (en) 2012-12-06
TW200822924A (en) 2008-06-01

Similar Documents

Publication Publication Date Title
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
CR11819A (es) Compuestos de isoindolina 5-sustituidos
UY30327A1 (es) Nuevos compuestos ii
DOP2010000387A (es) Compuestos pirazolicos 436
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
ECSP088296A (es) Compuestos terapéuticos
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY30500A1 (es) Compuestos de azabencimidazolilo
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY30460A1 (es) Compuestos terapéuticos
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CR11861A (es) Compuestos organicos
UY31189A1 (es) Compuestos heterocíclicos
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)